Dr. Andrew Lipman Co-Author of Phase 2 Study on Bendamustine, Bortezomib, Rituximab Combination for Low Grade Lymphoma
- Amanda Bridges
- March 2, 2018
- News
Naples, FL – March 1, 2018…… Dr. Andrew Lipman, who practices at Florida Cancer Specialists (FCS) in Bonita Springs and Naples West offices, was a co-author of a research paper evaluating the safety and efficacy of combining three drug agents – bendamustine, bortezomib and rituximab (BBR) – in patients with previously untreated low-grade lymphoma. Published January 2018 in the British Journal of Haematology, the study focused on a Phase II trial, in which eligible patients had low grade lymphoma with no previous systemic disease treatment. According to theLeukemia Lymphoma Society (LLS), about 40% of non-Hodgkin lymphoma (NHL) are categorized as low grade.
Each of the three agents in this study has shown previous benefit to patients. Bendamustine, a bi-functional anti-neoplastic agent has demonstrated clinical activity in patients with advanced indolent NHL. The monoclonal antibody Rituximab, in combination with standard chemotherapy regimens, has improved response rates and survival when used for indolent NHL and diffuse large B-cell lymphoma. Further, the combination of bendamustine and rituximab (BR) has been shown to be as effective or superior to certain other agents in low-grade and mantle cell lymphoma.
The third drug, Bortezomib, is a reversible 26S proteasome inhibitor that is approved for the treatment of multiple myeloma and mantle cell lymphoma. The study states, “It has been shown to have significant activity in a broad array of patients with NHL… Given this data, the combination of all three agents (bendamustine, bortezomib and rituximab [BBR]) was evaluated in patients with relapsed/refractory indolent NHL and mantle cell lymphoma with promising results.”
According to the study, “The combination of bendamustine, bortezomib and rituximab (BBR) produced deep and durable remissions with an acceptable safety profile in patients with previously untreated, low grade lymphoma. Progression free survival (PFS) was durable at 36 months where 75% of patients have not progressed. The BBR drug combination produced high CR rates which compare favorably to a recent Phase III trial using bendamustine plus rituximab (Flinn et al, 2014).”
The study concluded that because the BBR combination was well-tolerated and “produced high overall and complete response rates in a front-line setting, … this regimen merits further investigation in patients with previously untreated low-grade lymphoma, as well as, potentially, patients with mantle-cell lymphoma.”
To access the complete article: http://onlinelibrary.wiley.com/doi/10.1111/bjh.15044/full
SOURCES:
British Journal of Haematology, 2018, 180, 365–373
Blood, 2014, 123, 2944–2952.
About Florida Cancer Specialists & Research Institute: (FLCancer.com)
Founded in 1984, Florida Cancer Specialists & Research Institute (FCS) is the largest independent medical oncology/hematology practice in the United States. With over 220 physicians, 180 nurse practitioners and physician assistants and nearly 100 locations in our network, we are committed to providing world-class cancer care in community-based settings close to home.
Recognized by the American Society of Clinical Oncology (ASCO) with a national Clinical Trials Participation Award, FCS offers patients access to more clinical trials than any private oncology practice in Florida. 84% of new cancer drugs approved in 2016 for use in the U.S. were studied in clinical trials conducted with FCS participation*. Our physicians are consistently ranked nationally as Top Doctors by U.S. News & World Report.Trained in such prestigious medical schools and research institutes as Duke, Stanford, Harvard, Emory, M.D. Anderson, and Memorial Sloan-Kettering, the physicians of Florida Cancer Specialists provide leadership and consultation in the state’s leading hospitals.
FCS serves patients on the Gulf Coast from Naples to the greater Tampa Bay area, north as far as Tallahassee, in Orlando and surrounding Central Florida communities, and on the East Coast from Jacksonville/Fleming Island to Palm Beach County.
Florida Cancer Specialists has built a national reputation for excellence that is reflected in exceptional and compassionate patient care, driven by innovative clinical research and cutting-edge technologies that help advance targeted treatments and genetically-based immunotherapies, and embodied by our outstanding team of highly-trained and dedicated physicians, clinicians and staff.
* Prior to approval
Florida Cancer Specialists & Research Institute
Shelly Glenn, Chief Marketing & Sales Officer – SGlenn@FLCancer.com
770.365.6168
ChappellRoberts
Chris Wilkerson – cwilkerson@chappellroberts.com
813.334.6690
Ganick Communications, Inc.
Elaine Ganick – elaine@ganick.com
615.377.7877
